Digital Health Works Insights
US Market Entry for Medtech
How to choose accounts, buyers, channels, and proof before the first US launch push
US market entry for medtech is often framed like expansion into a large territory. In practice, it is an exercise in selecting the right buying environments before commercial noise and expense pile up.
The United States is not one market with one buyer path. It is a set of account types, reimbursement environments, procurement norms, channel structures, and implementation expectations.
For a medtech company entering the US, the first commercial goal should not be "cover the market." It should be to prove a repeatable buyer path.
Start with the first account type, not the full country
The best early question is usually:
Which account type should care first, and why?
That answer might point to:
- academic medical centers
- integrated delivery networks
- specialty clinics
- imaging centers
- ambulatory settings
- strategic distribution channels
- procedure-specific centers of excellence
The point is to narrow the launch to a buying context where the value story is strongest and the operational burden is realistic.
A broad launch creates activity. A focused launch creates learning. The difference matters because early US market entry is usually expensive: travel, conferences, sales development, legal work, contracting, product support, and partner management can consume resources quickly.
The buyer path matters more than market size
Before expanding outreach, a medtech team should be able to describe:
- the clinical problem being solved
- the stakeholder who feels that problem most acutely
- the budget owner or economic buyer
- the procurement or approval path
- the evidence story required for the purchase
- the implementation questions likely to surface
- the support model required after go-live
Without that map, US market entry becomes a long list of conversations that never mature.
The buyer path should also identify who can say no. In healthcare, the person who likes the product is not always the person who can approve the purchase. IT, finance, procurement, compliance, legal, and operations may all have real influence. A good US entry strategy prepares for those stakeholders before the first serious account conversation.
Reimbursement and budget are separate questions
For many medtech teams, US market entry starts with reimbursement. That makes sense, but it is not enough.
Reimbursement can support adoption, but the buyer still needs to understand workflow, cost, evidence, procurement, training, and risk. A reimbursement story that does not connect to a buying process will not carry the launch by itself.
Teams should ask:
- Is payment available, uncertain, indirect, or irrelevant to the first buyer?
- Does the buyer control the budget that will pay for the product?
- Does the product create value through revenue, cost avoidance, capacity, quality, risk reduction, or patient experience?
- What evidence does the buyer need to defend the decision?
- What assumptions need to be validated before scaling sales?
These questions help prevent the common mistake of confusing market potential with account readiness.
Channel strategy comes early
US market entry also forces a channel choice. Not always a final one, but an initial one.
Should the first motion be:
- founder-led commercial discovery
- direct sales
- distributor-led selling
- manufacturer sales representation
- strategic partnership development
That decision changes the materials, margin expectations, training needs, and support model that the company has to prepare.
Distributors can be valuable, but they are not magic. A distributor may help reach accounts, but the company still needs a clear value proposition, training package, support process, pricing logic, and procurement-ready evidence. If the product requires deep clinical education or workflow redesign, the company may need more direct involvement than expected.
Build the first US proof package
The first proof package should help a buyer understand why to act and how to adopt.
It should usually include:
- a concise account thesis
- stakeholder-specific value messaging
- clinical and economic evidence
- implementation plan
- procurement and security documentation
- support responsibilities
- pricing and contracting logic
- reference-account or pilot-conversion plan
This package does not need to be perfect before the first conversation. It does need to improve with every serious account conversation.
Practical takeaway
US market entry becomes more effective when teams stop treating it as a broad launch and start treating it as a commercialization system with a specific first buyer path.
The more clearly you can define the first accounts, buyer logic, proof requirements, channel fit, and support model, the faster the first real revenue conversations become.
Read this article on Digital Health Works